Scientists at Boehringer Ingelheim GmbH have made the ketohexokinase (KHK) inhibitor BI-9787 freely available as a tool compound via the company’s Opnme program.

Pinetree Therapeutics Inc. has entered into an exclusive option and global license agreement with Astrazeneca plc for a preclinical epidermal growth factor receptor (EGFR) degrader candidate.

Ipsen SA and Foreseen Technology (Beijing) Co. Ltd. have entered into an exclusive global licensing agreement for FS-001, an antibody-drug conjugate (ADC) that targets a novel tumor-associated antigen highly expressed across a range of solid tumors that was identified through the application of Foreseen’s proprietary proteomic platforms.

Immutep Ltd. has signed a license agreement with Cardiff University granting the company exclusive rights to develop and commercialize anti-LAG-3 small molecules.

Alivexis Inc. and Melodia Therapeutics AG have entered into an exclusive license agreement for the worldwide development, manufacturing and commercialization of Alivexis’ MDI-0151, a novel cathepsin C inhibitor identified in Alivexis’ MOD-A discovery program.

Day One Biopharmaceuticals Inc. has entered into an exclusive licensing agreement with Mabcare Therapeutics for MTX-13, a novel antibody-drug conjugate (ADC) targeting protein-tyrosine kinase 7 (PTK7). Under the agreement, Day One has exclusive rights to develop, manufacture and commercialize MTX-13 (now DAY-301), worldwide, excluding Greater China.

Bristol Myers Squibb Co. has exercised its option for an exclusive global license for PRX-019, a potential treatment of neurodegenerative diseases with an undisclosed target, under an agreement with Prothena Corp. plc.

Owkin Inc. has in-licensed OKN-4395 (ACT-1002-4391), a highly selective and potent dual inhibitor of prostanoid receptors EP2 and EP4, from Idorsia Ltd.

Evergreen Theragnostics Inc. has entered into a collaboration and licensing agreement with the Medical University of Innsbruck (MUI) to advance the development of novel radiopharmaceuticals.